Multiple Myeloma

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

By

Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

By

Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.

Early Results Suggest That Once-Weekly, High-Dose Carfilzomib Prolongs PFS in Multiple Myeloma

Early Results Suggest That Once-Weekly, High-Dose Carfilzomib Prolongs PFS in Multiple Myeloma

By

In the phase 3 ARROW study patients with relapsed/refractory multiple myeloma were randomly assigned to receive carfilzomib 27 mg/m2 twice-weekly or 70 mg/m2 once-weekly

Daratumumab Plus Carfilzomib, Dexamethasone May Be Effective in Lenalidomide-Refractory Multiple Myeloma

Daratumumab Plus Carfilzomib, Dexamethasone May Be Effective in Lenalidomide-Refractory Multiple Myeloma

By

The increase in use of lenalidomide as maintenance treatment emphasizes the need to explore additional treatment options among patients with lenalidomide-refractory multiple myeloma.

Pomalidomide Plus Bortezomib, Dexamethasone Prolongs PFS in Relapsed/Refractory Multiple Myeloma

Pomalidomide Plus Bortezomib, Dexamethasone Prolongs PFS in Relapsed/Refractory Multiple Myeloma

By

Researchers randomly assigned 559 patients with relapsed/refractory multiple myeloma to receive bortezomib and dexamethasone with or without pomalidomide.

Can Oncolytic Viruses Improve Immunotherapies?

Can Oncolytic Viruses Improve Immunotherapies?

By

Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.

Daratumumab and Elotuzumab: Potential mAb Therapies for Multiple Myeloma

Daratumumab and Elotuzumab: Potential mAb Therapies for Multiple Myeloma

By

Daratumumab is moving from a monotherapy for relapsed and refractory myeloma to a potential frontline player in combination induction regimens. And on the horizon are investigational bispecific antibodies, mAb-drug conjugates, and CAR-T therapies that might offer new advances against what today remains an incurable disease.

Clonally Transmissible Cancers in Nature

Clonally Transmissible Cancers in Nature

By

While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.

Early Success Gives Hope for CAR T-Cell Therapy in Multiple Myeloma

Early Success Gives Hope for CAR T-Cell Therapy in Multiple Myeloma

By

Early trial results show that immunotherapy using chimeric antigen receptor (CAR) T-cell therapy may be effective in patients with multiple myeloma.

FDA Approves Daratumumab/VMP Combination as First-Line Therapy in Multiple Myeloma

FDA Approves Daratumumab/VMP Combination as First-Line Therapy in Multiple Myeloma

By

Daratumumab was previously approved for patients with multiple myeloma who had previously failed 1 or more lines of therapy.

Do 9/11 Firefighters Really Have A Higher Incidence of MGUS?

Do 9/11 Firefighters Really Have A Higher Incidence of MGUS?

By

The firefighting profession has previously been associated with a higher risk of MGUS and myeloma compared with the general population.

The Hunt for Effective Anticancer Vaccines

The Hunt for Effective Anticancer Vaccines

By

Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.

Lenalidomide Alone or With Dexamethasone Effective in Relapsed Multiple Myeloma

Lenalidomide Alone or With Dexamethasone Effective in Relapsed Multiple Myeloma

By

A study of 133 patients with multiple myeloma who experienced a first relapse compared the efficacy of long-term therapy lenalidomide alone vs with dexamethasone.

PANEX May Improve PFS in R/R Multiple Myeloma

PANEX May Improve PFS in R/R Multiple Myeloma

By

This treatment-expansion study evaluated the tolerability and safety of the PANEX (panobinostat plus bortezomib with dexamethasone) protocol in heavily treated patients with R/R multiple myeloma.

HIV-Associated Cancers: A Paradigm Shift?

HIV-Associated Cancers: A Paradigm Shift?

By

Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

By

Most tumors do not respond, or evolve resistance, to immune checkpoint inhibition. Now, researchers at Johns Hopkins have engineered a new class of cancer immunotherapy agents designed to short-circuit key mechanisms of tumors' disruption and evasion of immune system attack.

Phase 1 Trials: Therapy, Not Just Science

Phase 1 Trials: Therapy, Not Just Science

By

Phase 1 trials should be considered therapeutic options for some patients.

Immunotherapy and the Risk of Myocarditis

Immunotherapy and the Risk of Myocarditis

By

The risk should not discourage patients with cancer from taking these potentially life-extending therapies.

Bortezomib Maintenance May Not Prolong PFS in Transplant-Ineligible Myeloma

Bortezomib Maintenance May Not Prolong PFS in Transplant-Ineligible Myeloma

By

After a median follow-up of 30.7 months, median overall survival from induction therapy initiation had not been reached.

Clostridium Difficile Infection in Patients With Cancer — In the Clinic

Clostridium Difficile Infection in Patients With Cancer — In the Clinic

By

While CDI is becoming more common in all hospitalized patients, patients with cancer appear to be at an elevated risk.

Can A Consortium of Hospitals Help To Reduce Drug Prices?

Can A Consortium of Hospitals Help To Reduce Drug Prices?

By

To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.

Are African-American and Hispanic Patients With Myeloma Receiving the Best Care?

Are African-American and Hispanic Patients With Myeloma Receiving the Best Care?

By

Patient outcomes following the diagnosis of multiple myeloma have improved markedly over recent years, but racial and ethnic disparities exist.

Diagnosing Medicine's Intractable Gender Pay Gap

Diagnosing Medicine's Intractable Gender Pay Gap

By

The #MeToo movement has inspired many women to relate stories of harassment, and medicine is no exception.

Cognitive Impairment Worsens Survival Among Elderly Patients With Hematologic Cancer

Cognitive Impairment Worsens Survival Among Elderly Patients With Hematologic Cancer

By

A variety of cognitive impairments are common in the elderly US population, with as many as 14% of individuals over 70 being affected by dementia.

Triplet Therapy With Ixazomib Shows Promise for Multiple Myeloma

Triplet Therapy With Ixazomib Shows Promise for Multiple Myeloma

By

Notably, peripheral neuropathy — a common AE with proteasome inhibitors — had a low occurrence rate.

Should the General Population Be Screened for MGUS?

Should the General Population Be Screened for MGUS?

By

Still unresolved is whether to screen the general population for MGUS, a largely asymptomatic condition usually noted during routine blood testing.

Managing Adverse Events in the Era of Immunotherapy

Managing Adverse Events in the Era of Immunotherapy

By

The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.

Healthful Lifestyles and Cancer: Much More Than A Single Behavior

Healthful Lifestyles and Cancer: Much More Than A Single Behavior

By

A recent study is the first to demonstrate the cumulative effect of a large number of lifestyle behaviors.

Cancer Immunosurveillance Comes of Age

Cancer Immunosurveillance Comes of Age

By

As oncologists learn to target the immune response to "self and non-self," a delicate therapy balance will eventually be achieved with predictable outcomes, benefits, and toxicity in the fight against cancer.

Pomalidomide Shows Activity, Toxicity in Patients With Myeloma and Renal Impairment

Pomalidomide Shows Activity, Toxicity in Patients With Myeloma and Renal Impairment

By

Pomalidomide, an immunomodulatory agent with anti-myeloma activity, is metabolized primarily by the liver, suggesting that patients with renal impairment can safely receive the drug.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs